Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amphotericin B oral - iCo Therapeutics

Next Previous
Drug Profile

Amphotericin B oral - iCo Therapeutics

Alternative Names: iCo-009; iCo-010; iCo-019; Oral AmpB; Oral AmpB delivery system; Oral amphotericin B delivery system

Latest Information Update: 28 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of British Columbia
  • Developer iCo Therapeutics
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Visceral leishmaniasis
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV-1 infections; Mycoses; Visceral leishmaniasis

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for phase-I development in Mycoses(In volunteers) in Australia (PO, Capsule)
  • 13 Jul 2020 Adverse events data from a phase 1b trial in Mycoses (In volunteers) released by iCo Therapeutics
  • 15 Apr 2020 Pharmacokinetics and adverse events data from a phase Ib trial in Mycoses (In volunteers) released by iCo Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top